Most Read Articles
16 May 2019
Empagliflozin treatment in patients with type 2 diabetes mellitus exerts beneficial effects on cardiovascular (CV) risk factors, including blood pressure and uric acid, according to a systematic review and meta-analysis.
Pearl Toh, 17 May 2019
Metformin continues to protect high-risk individuals from developing type 2 diabetes (T2D) over 15 years, especially among those with higher glycaemic status at baseline and women reporting a history of gestational diabetes mellitus (GDM), according to long-term results from DPP/DPPOS*.
16 May 2019
Due to the increasing global prevalence of obesity, older adults may live more years of their remaining life with limited physical function and activities in daily living (ADLs), according to a study, adding that older adults, their families and healthcare systems should be aware of this problem.
Jairia Dela Cruz, 6 days ago
One anastomosis gastric bypass is as effective as the standard Roux-en-Y procedure in terms of weight loss and metabolic improvements 24 months after the surgery, according to the results of the open-label YOMEGA trial.

Low-intensity resistance training improves muscle strength, glycaemic function in elderly diabetics

10 Sep 2018

Low-intensity resistance training is effective at improving muscle size and strength and glycaemic function in elderly type 2 diabetes patients, a recent study has found.

Nine type 2 diabetes patients (mean age 68.2±9.7 years; 5 males) were recruited and underwent low-intensity resistance training two times a week for 16 weeks. Study outcomes included body weight, fat mass, lean body mass, knee extension and flexion strengths, and changes in fasting HbA1c levels. Wilcoxon signed-rank tests were used to evaluate the changes in outcome variables over time.

The low-intensity resistance training programme demonstrated a significant effect on several measures of body composition. For instance, mean body weight dropped significantly from 65.0±8.7 to 64.1±8.4 kg following the intervention (p=0.0499).

Similarly, significant 16-week reductions were observed for body fat mass (21.2±5.0 to 20.2±5.0 kg; p=0.012) and body fat percentage (32.8±6.8 percent to 31.5±6.6 percent; p=0.012), while significant increases were recorded for total lean body mass (63.6±6.6 percent to 64.7±6.5 percent; p=0.012) and lean body mass of the trunk (30.3±3.5 percent to 31.4±4.1 percent; p=0.017).

Significant improvements in muscle strength were also observed, both for isokinetic knee extension (angular velocity: 60o/s: 72.9±32.1 to 80.4±28.4 N·m; p=0.015; 180o/s: 46.3±17.7 to 52.7±19.6 N·m; p=0.021) and flexion (angular velocity: 60o/s: 42.7±20.7 to 50.9±20.2 N·m; p=0.012; 180o/s: 25.3±12.4 to 36.2±12.3 N·m; p=0.008).

The same was true for maximum leg press strength (62.4±19.9 to 101.2±22.7; p=0.008). In contrast, the 16-week exercise regimen had no significant effect on HbA1c (7.1±0.5 percent to 6.8±0.4 percent; p=0.066) and fasting plasma glucose (124.8±16.5 to 129.6±31.2 mg/dL; p=0.767).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
16 May 2019
Empagliflozin treatment in patients with type 2 diabetes mellitus exerts beneficial effects on cardiovascular (CV) risk factors, including blood pressure and uric acid, according to a systematic review and meta-analysis.
Pearl Toh, 17 May 2019
Metformin continues to protect high-risk individuals from developing type 2 diabetes (T2D) over 15 years, especially among those with higher glycaemic status at baseline and women reporting a history of gestational diabetes mellitus (GDM), according to long-term results from DPP/DPPOS*.
16 May 2019
Due to the increasing global prevalence of obesity, older adults may live more years of their remaining life with limited physical function and activities in daily living (ADLs), according to a study, adding that older adults, their families and healthcare systems should be aware of this problem.
Jairia Dela Cruz, 6 days ago
One anastomosis gastric bypass is as effective as the standard Roux-en-Y procedure in terms of weight loss and metabolic improvements 24 months after the surgery, according to the results of the open-label YOMEGA trial.